{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:28:57Z","timestamp":1786987737991,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.det.2022.07.012","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T16:08:39Z","timestamp":1668787719000},"page":"141-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cutaneous Oncology in the Immunosuppressed"],"prefix":"10.1016","volume":"41","author":[{"given":"Leo L.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Stull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuzar M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. William","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerrene N.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Etzkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.det.2022.07.012_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-014-0085-5","article-title":"Optimal management of skin cancer in immunosuppressed patients","volume":"15","author":"Brin","year":"2014","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.det.2022.07.012_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/ijd.12208","article-title":"Lymphoma-associated skin cancer: incidence, natural history, and clinical management","volume":"53","author":"Brewer","year":"2014","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib3","first-page":"129","article-title":"Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic leukemia and solid-organ transplantation","volume":"29","author":"Mehrany","year":"2003","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.det.2022.07.012_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00042728-200501000-00008","article-title":"High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia","volume":"31","author":"Mehrany","year":"2005","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.det.2022.07.012_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamadermatol.2013.6249","article-title":"Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia","volume":"150","author":"Velez","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib6","first-page":"260","article-title":"HPV Carcinomas in Immunocompromised Patients","volume":"4","author":"Reusser","year":"2015","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.det.2022.07.012_bib7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamadermatol.2017.1716","article-title":"Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load","volume":"153","author":"Asgari","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.det.2022.07.012_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/cid\/civ628","article-title":"Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in hiv-positive men who have sex with men","volume":"61","author":"Deshmukh","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.det.2022.07.012_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.11.063","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"17","key":"10.1016\/j.det.2022.07.012_bib12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju382","article-title":"Risk of merkel cell carcinoma after solid organ transplantation","volume":"107","author":"Clarke","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.det.2022.07.012_bib16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/tri.13520","article-title":"Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines","volume":"32","author":"Crow","year":"2019","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.det.2022.07.012_bib17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/TP.0000000000001286","article-title":"Association of pretransplant skin cancer with posttransplant malignancy, graft failure and death in kidney transplant recipients","volume":"101","author":"Kang","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.det.2022.07.012_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamadermatol.2021.3180","article-title":"Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients: a delphi consensus statement","volume":"157","author":"Massey","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.det.2022.07.012_bib20","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/jid.2015.312","article-title":"Melanoma risk and survival among organ transplant recipients","volume":"135","author":"Robbins","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"10.1016\/j.det.2022.07.012_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archdermatol.2011.159","article-title":"Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis","volume":"147","author":"Brewer","year":"2011","journal-title":"Arch Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.det.2022.07.012_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","article-title":"Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study","volume":"161","author":"Ulrich","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2022.07.012_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ajt.13978","article-title":"Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines","volume":"17","author":"Acuna","year":"2017","journal-title":"Am J Transpl"},{"issue":"12","key":"10.1016\/j.det.2022.07.012_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/tri.13493","article-title":"Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study","volume":"32","author":"Jambusaria-Pahlajani","year":"2019","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.det.2022.07.012_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.07087.x","article-title":"Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey","volume":"154","author":"Otley","year":"2006","journal-title":"Br J Dermatol"},{"issue":"25","key":"10.1016\/j.det.2022.07.012_bib26","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results","volume":"36","author":"Dantal","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2022.07.012_bib27","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/ajt.13596","article-title":"Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort","volume":"16","author":"Coghill","year":"2016","journal-title":"Am J Transpl"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2022.07.012_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1054\/bjoc.2001.1931","article-title":"Non-melanoma skin cancers and glucocorticoid therapy","volume":"85","author":"Karagas","year":"2001","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.det.2022.07.012_bib31","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.det.2022.07.012_bib32","first-page":"E32","article-title":"Systemic medications linked to an increased risk for skin malignancy","volume":"104","author":"Johnson","year":"2019","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.det.2022.07.012_bib33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamadermatol.2020.1141","article-title":"Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States","volume":"156","author":"D'Arcy","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaad.2020.04.160","article-title":"Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses","volume":"84","author":"Tee","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2022.07.012_bib35","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin Cancers in Organ Transplant Recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am J Transpl"},{"issue":"6","key":"10.1016\/j.det.2022.07.012_bib36","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jdcr.2015.09.009","article-title":"Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients","volume":"1","author":"Breithaupt","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2022.07.012_bib37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.12688\/f1000research.11314.1","article-title":"Emerging concepts and recent advances in basal cell carcinoma","volume":"6","author":"Totonchy","year":"2017","journal-title":"F1000Res"},{"issue":"7","key":"10.1016\/j.det.2022.07.012_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jamadermatol.2019.0032","article-title":"Performance of the american joint committee on cancer staging manual, 8th edition vs the brigham and women's hospital tumor classification system for cutaneous squamous cell carcinoma","volume":"155","author":"Ruiz","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib39","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.det.2022.07.012_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamadermatol.2013.2456","article-title":"Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system","volume":"149","author":"Jambusaria-Pahlajani","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2022.07.012_bib41","series-title":"TNM classification of malignant tumours","author":"Sobin","year":"2011"},{"issue":"3","key":"10.1016\/j.det.2022.07.012_bib42","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2021.01.052","article-title":"Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death","volume":"85","author":"Morgan","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2022.07.012_bib43","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1524-4725.2012.02574.x","volume":"38","author":"American Academy of D","year":"2012","journal-title":"Dermatol Surg"},{"issue":"10","key":"10.1016\/j.det.2022.07.012_bib44","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamadermatol.2021.3020","article-title":"Evaluation of watchful waiting and tumor behavior in patients with basal cell carcinoma: an observational cohort study of 280 basal cell carcinomas in 89 patients","volume":"157","author":"van Winden","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2022.07.012_bib45","doi-asserted-by":"crossref","first-page":"e125476","DOI":"10.1172\/jci.insight.125476","article-title":"Skin cancer precursor immunotherapy for squamous cell carcinoma prevention","volume":"4","author":"Rosenberg","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.det.2022.07.012_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjoto.2017.01.035","article-title":"Rate of regional nodal metastases of cutaneous squamous cell carcinoma in the immunosuppressed patient","volume":"38","author":"McLaughlin","year":"2017","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2016.08.051","article-title":"The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management","volume":"76","author":"Ruiz","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2022.07.012_bib48","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.3747\/co.27.6015","article-title":"Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"27","author":"Claveau","year":"2020","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.det.2022.07.012_bib49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/DSS.0000000000002965","article-title":"A\u00a0Systematic review of primary, adjuvant, and salvage radiation therapy for cutaneous squamous cell carcinoma","volume":"47","author":"Krausz","year":"2021","journal-title":"Dermatol Surg"},{"issue":"11","key":"10.1016\/j.det.2022.07.012_bib50","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/cncr.30601","article-title":"A\u00a0multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck","volume":"123","author":"Manyam","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.det.2022.07.012_bib51","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.det.2022.07.012_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.det.2022.07.012_bib53","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.det.2022.07.012_bib54","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.healun.2007.09.019","article-title":"Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab","volume":"26","author":"Leard","year":"2007","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"6","key":"10.1016\/j.det.2022.07.012_bib55","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.det.2022.07.012_bib56","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/fon-2020-0823","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","volume":"17","author":"Keeping","year":"2021","journal-title":"Future Oncol"},{"issue":"13","key":"10.1016\/j.det.2022.07.012_bib57","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","article-title":"Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial","volume":"36","author":"Porceddu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.det.2022.07.012_bib58","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transpl"},{"issue":"7","key":"10.1016\/j.det.2022.07.012_bib59","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib60","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.det.2022.07.012_bib61","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2022.07.012_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamadermatol.2014.1894","article-title":"Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient","volume":"151","author":"Cusack","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.012_bib63","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaad.2018.11.008","article-title":"The rule of 10s versus the rule of 2s: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas","volume":"85","author":"Rzepecki","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"18","key":"10.1016\/j.det.2022.07.012_bib64","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2022.07.012_bib65","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjd.17783","article-title":"Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report","volume":"181","author":"Ressler","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2022.07.012_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaad.2017.06.031","article-title":"Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies","volume":"78","author":"Tripathi","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2022.07.012_bib67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/jid.2012.388","article-title":"Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage","volume":"133","author":"Paulson","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9305","key":"10.1016\/j.det.2022.07.012_bib68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(02)07668-7","article-title":"Merkel cell carcinoma and HIV infection","volume":"359","author":"Engels","year":"2002","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.det.2022.07.012_bib70","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/cncr.30475","article-title":"Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study","volume":"123","author":"Paulson","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.det.2022.07.012_bib71","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2022.07.012_bib72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.det.2022.07.012_bib73","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1097\/00007890-200005150-00008","article-title":"Outcome of kidney transplant recipients with previous human herpesvirus-8 infection","volume":"69","author":"Frances","year":"2000","journal-title":"Transplantation"},{"issue":"19","key":"10.1016\/j.det.2022.07.012_bib74","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM199811053391903","article-title":"Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients","volume":"339","author":"Regamey","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.det.2022.07.012_bib75","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2022.07.012_bib76","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00432-020-03433-1","article-title":"The previously common post-kidney transplant Kaposi sarcoma has become non-existent for a decade: an Egyptian experience","volume":"147","author":"Donia","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352200064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352200064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:46:26Z","timestamp":1760006786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386352200064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S073386352200064X"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2022.07.012","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Oncology in the Immunosuppressed","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2022.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}